StocksFundsScreenerSectorsWatchlists
STAA

STAA - STAAR Surgical Co Stock Price, Fair Value and News

49.79USD-1.81 (-3.51%)Market Closed

Market Summary

STAA
USD49.79-1.81
Market Closed
-3.51%

STAA Alerts

  • 1 major insider buys recently.

STAA Stock Price

View Fullscreen

STAA RSI Chart

STAA Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

113.98

Price/Sales (Trailing)

7.55

EV/EBITDA

57.98

Price/Free Cashflow

-676.97

STAA Price/Sales (Trailing)

STAA Profitability

EBT Margin

10.45%

Return on Equity

5.53%

Return on Assets

4.37%

Free Cashflow Yield

-0.15%

STAA Fundamentals

STAA Revenue

Revenue (TTM)

322.4M

Rev. Growth (Yr)

19.09%

Rev. Growth (Qtr)

-5.02%

STAA Earnings

Earnings (TTM)

21.3M

Earnings Growth (Yr)

14.68%

Earnings Growth (Qtr)

61.01%

Breaking Down STAA Revenue

Last 7 days

2.3%

Last 30 days

30.5%

Last 90 days

57.1%

Trailing 12 Months

-25.9%

How does STAA drawdown profile look like?

STAA Financial Health

Current Ratio

5.62

STAA Investor Care

Shares Dilution (1Y)

1.31%

Diluted EPS (TTM)

0.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023294.7M305.9M310.2M322.4M
2022242.9M261.7M279.3M284.4M
2021179.0M206.2M217.5M230.5M
2020152.8M148.3M156.3M163.5M
2019129.4M135.2M142.5M150.2M
201897.4M109.3M117.6M124.0M
201783.5M84.5M87.9M90.6M
201677.5M79.9M81.2M82.4M
201573.7M72.3M72.8M77.1M
201474.4M76.3M77.4M75.0M
201366.3M68.5M69.7M72.2M
201263.4M63.1M63.7M63.8M
201156.0M58.7M60.8M62.8M
2010052.4M53.7M55.0M
200900051.1M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of STAAR Surgical Co

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 14, 2024
weisner aimee s
bought
66,692
38.11
1,750
-
Mar 12, 2024
butcher arthur c
acquired
-
-
649
-
Mar 12, 2024
jiang wei
acquired
-
-
1,299
-
Mar 07, 2024
williams patrick f.
acquired
-
-
2,614
chief financial officer
Jan 08, 2024
broadwood partners, l.p.
bought
-
-
-
-
Jan 08, 2024
broadwood partners, l.p.
bought
109,570
27.1079
4,042
-
Jan 05, 2024
broadwood partners, l.p.
bought
4,463,230
28.4765
156,734
-
Jan 05, 2024
broadwood partners, l.p.
bought
-
-
-
-
Jan 04, 2024
broadwood partners, l.p.
bought
-
-
-
-
Jan 04, 2024
broadwood partners, l.p.
bought
1,828,180
28.9059
63,246
-

1–10 of 50

Which funds bought or sold STAA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 09, 2024
MASSMUTUAL TRUST CO FSB/ADV
new
-
1,225
1,225
-%
Apr 09, 2024
MATHER GROUP, LLC.
new
-
312
312
-%
Apr 09, 2024
Rise Advisors, LLC
unchanged
-
424
2,297
-%
Apr 05, 2024
CWM, LLC
added
23.25
4,000
11,000
-%
Apr 05, 2024
GAMMA Investing LLC
added
313
41,219
50,070
0.01%
Apr 04, 2024
Financial Synergies Wealth Advisors, Inc.
unchanged
-
485
2,816
-%
Apr 03, 2024
Versant Capital Management, Inc
new
-
1,837
1,837
-%
Apr 02, 2024
M&R CAPITAL MANAGEMENT INC
sold off
-100
-687
-
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-97.95
-148,472
2,403
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
new
-
1,435,660
1,435,660
-%

1–10 of 45

Are Funds Buying or Selling STAA?

Are funds buying STAA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own STAA
No. of Funds

Unveiling STAAR Surgical Co's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
11.20%
5,468,710
SC 13G/A
Jan 26, 2024
baillie gifford & co
9.11%
4,448,208
SC 13G/A
Jan 22, 2024
blackrock inc.
16.7%
8,159,763
SC 13G/A
Jan 10, 2024
broadwood partners, l.p.
22.1%
0
SC 13D/A
Nov 15, 2023
broadwood partners, l.p.
20.7%
0
SC 13D/A
Oct 10, 2023
broadwood partners, l.p.
19.5%
0
SC 13D/A
Sep 07, 2023
blackrock inc.
17.2%
8,328,302
SC 13G/A
Feb 09, 2023
vanguard group inc
11.01%
5,306,915
SC 13G/A
Jan 23, 2023
blackrock inc.
11.9%
5,738,044
SC 13G/A
Jan 19, 2023
baillie gifford & co
10.87%
5,240,456
SC 13G/A

Recent SEC filings of STAAR Surgical Co

View All Filings
Date Filed Form Type Document
Apr 04, 2024
8-K
Current Report
Mar 18, 2024
8-K
Current Report
Mar 15, 2024
UPLOAD
UPLOAD
Mar 14, 2024
4
Insider Trading
Mar 14, 2024
4
Insider Trading
Mar 14, 2024
4
Insider Trading
Mar 14, 2024
4
Insider Trading
Mar 14, 2024
4
Insider Trading
Mar 14, 2024
4
Insider Trading
Mar 14, 2024
4
Insider Trading

Peers (Alternatives to STAAR Surgical Co)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
189.3B
40.1B
-9.21% 5.29%
33.08
4.72
-8.12% -17.45%
67.9B
19.5B
-1.55% -8.27%
54.08
3.48
4.02% -22.04%
23.7B
3.9B
-1.72% -7.67%
53.19
6.13
3.42% 23.09%
20.5B
14.8B
-5.55% -6.65%
7.71
1.38
2.12% 209.17%
MID-CAP
9.1B
12.3B
-5.72% -13.98%
21.94
0.74
-2.44% -22.68%
9.1B
3.5B
-2.81% 14.53%
31.84
2.6
4.97% 18.89%
8.8B
2.7B
-10.75% -38.18%
-13.76
3.28
-4.68% 82.43%
6.5B
4.0B
-8.29% -23.99%
-48.26
1.64
1.10% 85.84%
3.4B
366.4M
-0.38% 19.00%
-567.94
9.41
33.86% 89.83%
2.3B
6.6B
-5.95% -4.86%
11.79
0.35
2.78% -0.87%
SMALL-CAP
1.3B
3.2B
-4.92% -19.00%
-1.93
0.41
7.73% -1066.14%
372.1M
166.7M
-1.34% -7.94%
-4.5
2.23
6.67% -456.34%
255.5M
324.0M
14.75% -32.34%
-1.33
0.79
-3.19% -337.41%
49.2M
52.3M
-18.86% -53.44%
-2.63
0.94
17.61% 19.28%
4.0M
3.7M
-9.04% 297.37%
-0.32
1.06
5.77% 8.23%

STAAR Surgical Co News

Latest updates
Yahoo Movies Canada13 Apr 202403:33 am
Yahoo Movies Canada11 Apr 202401:21 pm
MarketBeat11 Apr 202412:27 pm
InvestorsObserver11 Mar 202407:00 am

STAAR Surgical Co Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-5.0%76.0080.0092.0074.0064.0076.0081.0063.0059.0058.0062.0051.0046.0047.0035.0035.0039.0039.0040.0033.0031.00
Gross Profit-4.6%61.0064.0071.0058.0050.0060.0064.0049.0045.0045.0049.0039.0034.0035.0024.0025.0029.0029.0030.0024.0023.00
  S&GA Expenses-12.2%50.0057.0062.0055.0049.0047.0047.0037.0038.0037.0039.0032.0030.0030.0025.0026.0026.0026.0025.0023.0022.00
  R&D Expenses-5.3%11.0011.0012.0010.0010.0010.009.008.009.008.008.008.009.009.007.007.007.006.006.006.006.00
EBITDA Margin20.2%0.12*0.10*0.12*0.15*0.18*0.18*0.17*0.17*0.15*0.15*0.15*0.11*---------
Income Taxes210.2%6.002.002.002.00-0.782.002.002.00-0.961.002.001.001.001.001.00-1.16-3.401.001.000.000.00
Earnings Before Taxes103.7%14.007.008.005.006.0013.0015.0012.007.007.0011.006.005.005.00-0.62-1.293.003.005.002.001.00
EBT Margin25.0%0.10*0.08*0.10*0.13*0.16*0.17*0.16*0.15*0.14*0.13*0.13*0.09*---------
Net Income61.0%8.005.006.003.007.0010.0013.0010.005.006.009.005.003.004.00-1.17-0.136.002.004.001.001.00
Net Income Margin0.9%0.07*0.07*0.08*0.11*0.14*0.14*0.13*0.12*0.11*0.11*0.10*0.06*---------
Free Cashflow290.5%29.00-15.16-9.32-7.99-1.0518.008.00-7.154.0019.003.005.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets3.6%489472441419419395376351346325294266257235218207208193186177167
  Current Assets5.2%365347328313312297296274271264248224216196183172175165159153152
    Cash Equivalents43.6%18312795.0090.0086.00129202193200196173162152128116111120112103102104
  Net PPE6.3%67.0063.0056.0053.0051.0048.0043.0040.0036.0032.0029.0026.0024.0023.0021.0020.0017.0015.0013.0011.0011.00
  Goodwill0%2.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.00
Liabilities10.6%10393.0087.0080.0083.0075.0077.0075.0087.0075.0060.0052.0060.0048.0043.0042.0048.0043.0042.0040.0035.00
  Current Liabilities14.6%65.0057.0054.0047.0052.0045.0047.0041.0049.0047.0042.0036.0041.0034.0032.0030.0034.0030.0029.0028.0028.00
Shareholder's Equity1.9%386379358339336323302276262249235214197186175165160149144137132
  Retained Earnings14.1%-47.37-55.12-63.86-69.92-68.71-78.49-88.75-101-108-116-122-130-135-139-143-141-141-148-150-154-156
  Additional Paid-In Capital0.2%437436420409404398387379374369360348338328320309304300296293290
Shares Outstanding0.0%49.0049.0048.0048.0048.0048.0048.0048.0047.0047.0047.0047.00---------
Float---2,567---3,467---6,859---2,821---1,308--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations635.0%31,969-5,975-6,306-5,0942,97024,10913,246-4,6108,49822,3166,3826,76619,5509,589-17.00-8,1719,79311,7943,4777312,345
  Share Based Compensation-97.9%1828,8468,4236,0654,9965,7275,7543,8943,6203,6633,9923,3303,1813,1262,9182,9212,7692,5582,5792,6411,836
Cashflow From Investing-29.6%22,40231,84010,1729,933-46,717-101,849-5,271-2,539-4,689-3,273-3,524-2,159-2,145-2,049-2,025-2,185-2,979-2,568-2,398-2,233-524
Cashflow From Financing-94.8%3677,1071,302-1,3612024,9942,207894-2164,1767,8336,0006,5504,3177,4401,264828-111-328-240-446

STAA Income Statement

2023-12-29
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Net sales$ 322,415$ 284,391$ 230,472
Cost of sales69,76461,00851,835
Gross profit252,651223,383178,637
Selling, general and administrative expenses:   
General and administrative72,31954,74244,142
Selling and marketing107,83488,85667,294
Research and development44,40135,98333,862
Total selling, general and administrative expenses224,554179,581145,298
Operating income28,09743,80233,339
Other income (expense), net:   
Interest income (expense), net6,9862,448(38)
Loss on foreign currency transactions[1](1,909)(1,707)(2,964)
Royalty income748041,015
Other income (loss), net448205(48)
Total other income (expenses), net5,5991,750(2,035)
Income before income taxes33,69645,55231,304
Provision for income taxes12,3495,8873,793
Net income$ 21,347$ 39,665$ 27,511
Net income per share:   
Basic$ 0.44$ 0.83$ 0.58
Diluted$ 0.43$ 0.80$ 0.56
Weighted average shares outstanding:   
Basic48,52347,98747,210
Diluted49,42749,38049,456
[1]Shown as a separate line item on the Consolidated Statements of Income.

STAA Balance Sheet

2023-12-29
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 29, 2023
Dec. 30, 2022
Current assets:  
Cash and cash equivalents$ 183,038,000$ 86,480,000
Investments available for sale37,688,000125,159,000
Accounts receivable trade, net94,704,00062,447,000
Inventories, net35,130,00024,161,000
Prepayments, deposits and other current assets14,709,00013,476,000
Total current assets365,269,000311,723,000
Investments available for sale11,703,00013,902,000
Property, plant and equipment, net66,835,00050,921,000
Finance lease right-of-use assets, net183,000342,000
Operating lease right-of-use assets, net34,387,00030,270,000
Intangible assets, net 173,000
Goodwill1,786,0001,786,000
Deferred income taxes5,190,0008,744,000
Other assets3,339,000957,000
Total assets488,692,000418,818,000
Current liabilities:  
Accounts payable13,557,00011,576,000
Obligations under finance leases165,000169,000
Obligations under operating leases4,202,0003,524,000
Allowance for sales returns6,174,0005,706,000
Other current liabilities40,938,00030,741,000
Total current liabilities65,036,00051,716,000
Obligations under finance leases42,000210,000
Obligations under operating leases31,425,00027,136,000
Deferred income taxes1,077,0001,489,000
Asset retirement obligations103,000220,000
Pension liability5,055,0001,935,000
Total liabilities102,738,00082,706,000
Commitments and contingencies (Note 13)
Stockholders’ equity:  
Common stock, $0.01 par value; 60,000 shares authorized: 48,839 and 48,212 shares issued and outstanding at December 29, 2023 and December 30, 2022, respectively488,000482,000
Additional paid-in capital436,947,000404,189,000
Accumulated other comprehensive income (loss)(4,113,000)156,000
Accumulated deficit(47,368,000)(68,715,000)
Total stockholders’ equity385,954,000336,112,000
Total liabilities and stockholders’ equity$ 488,692,000$ 418,818,000
STAA
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
 CEO
 WEBSITEstaar.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES882

STAAR Surgical Co Frequently Asked Questions


What is the ticker symbol for STAAR Surgical Co? What does STAA stand for in stocks?

STAA is the stock ticker symbol of STAAR Surgical Co. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of STAAR Surgical Co (STAA)?

As of Fri Apr 12 2024, market cap of STAAR Surgical Co is 2.43 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STAA stock?

You can check STAA's fair value in chart for subscribers.

What is the fair value of STAA stock?

You can check STAA's fair value in chart for subscribers. The fair value of STAAR Surgical Co is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of STAAR Surgical Co is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for STAA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is STAAR Surgical Co a good stock to buy?

The fair value guage provides a quick view whether STAA is over valued or under valued. Whether STAAR Surgical Co is cheap or expensive depends on the assumptions which impact STAAR Surgical Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STAA.

What is STAAR Surgical Co's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, STAA's PE ratio (Price to Earnings) is 113.98 and Price to Sales (PS) ratio is 7.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STAA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on STAAR Surgical Co's stock?

In the past 10 years, STAAR Surgical Co has provided 0.114 (multiply by 100 for percentage) rate of return.